Drugs Channel
Topics & Medications
Quicklinks
Related Channels

Ruxolitinib

If you have intermediate-risk or high-risk myelofibrosis, ruxolitinib may be used to help relieve symptoms and reduce the size of your spleen. This prescription medicine comes in tablet form and is typically taken twice a day. It works by preventing the formation of abnormal blood cells. Most people who take this drug will experience some type of side effect, such as headaches, bruising, or dizziness.

What Is Ruxolitinib?

Ruxolitinib (Jakafi™) is a prescription medication approved to treat a disorder of the bone marrow known as myelofibrosis. Myelofibrosis is characterized by scarring of the bone marrow. Ruxolitinib is used to treat people who are considered intermediate-risk or high-risk, based on their expected survival. It belongs to a class of medicines known as kinase inhibitors.
 
(Click What Is Ruxolitinib Used For? for more information on this topic, including possible off-label uses.)
 

Are There Side Effects?

Just like any medicine, ruxolitinib can cause side effects. Although not everyone who takes this medication will have problems, most people will experience some type of side effect with this drug. Your healthcare provider can help you manage some of the reactions you may experience.
 
Common side effects of ruxolitinib include but are not limited to:
 
  • Low blood cell counts
  • Bruising
  • Dizziness
  • Headaches.
 
(Click Ruxolitinib Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider.)
 
7 Natural Ways to Reduce Your Cancer Pain

Ruxolitinib Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.